Enginechem Life Sciences to Pursue Global Licensing for Two New Drug Pipelines from Evixgen

AVI-3207 for Diabetic Macular Edema Treatment
AVI-4015 for Dry Eye Syndrome Treatment
Formation of Global Licensing Team

[Asia Economy Reporter Lee Gwan-ju] Engchem Life Sciences announced on the 21st that it has signed a strategic partnership agreement with new drug development company Evixgen and is promoting the global licensing of Evixgen's new drug pipelines AVI-3207 (wet age-related macular degeneration treatment) and AVI-4015 (dry eye syndrome treatment).

Evixgen was founded by Professor Yoo Ji-chang of the Catholic University College of Medicine, and is developing global innovative new drugs with immune-inflammatory disease-specific small molecule drugs and disease-targeted high-efficiency drug delivery system technologies.

The wet age-related macular degeneration treatment AVI-3207 was confirmed in comparative animal experiments to significantly inhibit angiogenesis with a dosage more than 20 times lower than Novartis's Lucentis and Bayer's Eylea. An Evixgen official explained, "All existing treatments are intravitreal injections, but AVI-3207, with its innovative drug delivery technology, enables retinal distribution through eye drops without piercing the patient's eye with a needle." The company also stated that the dry eye syndrome treatment AVI-4015 is a new molecular DDR1 modulator therapy that reduces inflammation, the cause of dry eye syndrome, and has a protective effect on goblet cells.

Additionally, Engchem Life Sciences recently recruited four global licensing experts. The global licensing team consists of Dr. Castellana, former Vice President of BMS; Dr. Hamrick, former Chief Medical Officer of the Capital division at HCA; Dr. Fleming, former FDA official; and Dr. McMenamin, an expert in medicine and law.

Engchem Life Sciences has successfully completed Phase 2 clinical trials for oral mucositis caused by chemoradiotherapy and is promoting global licensing. The company also holds a unique portfolio of 207 intellectual property rights in the fields of small molecule lipid drugs and immune-inflammatory diseases. Son Ki-young, Chairman of Engchem Life Sciences, said, "This year, we aim to realize the value of new drug development by successfully licensing EC-18 oral mucositis treatment and AVI-3207 wet age-related macular degeneration treatment globally."

This content was produced with the assistance of AI translation services.